CoChat

An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules

Open access
Harper, Jane, Adams, Katherine J., Bossi, Giovanna, Wright, Debbie E., Stacey, Andrea R., Bedke, Nicole, Martinez-Hague, Ruth, Blat, Dan, Humbert, Laure, Buchanan, Hazel, Le Provost, Gabrielle S., Donnellan, Zoe, Carreira, Ricardo J., Paston, Samantha J., Weigand, Luise U., Canestraro, Martina, Sanderson, Joseph P., Botta Gordon-Smith, Sophie, Lowe, Kate L., Rygiel, Karolina A., Powlesland, Alex S., Vuidepot, Annelise, Hassan, Namir J., Cameron, Brian J., Jakobsen, Bent K., Dukes, Joseph · 2018 · PLOS ONE
Cited by 84

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Robust preclinical testing is essential to predict clinical safety and efficacy and provide data to determine safe dose for first-in-man studies. There are a growing number of examples where the preclinical development of drugs failed to adequately predict clinical adverse events in part due to their assessment with inappropriate preclinical models. Preclinical investigations of T cell receptor (TCR)-based immunotherapies prove particularly challenging as these biologics are human-specific and thus the conventional testing in animal models is inadequate. As these molecules harness the full force of the immune system, and demonstrate tremendous potency, we set out to design a preclinical package that would ensure adequate evaluation of these therapeutics. Immune Mobilising Monoclonal TCR Against Cancer (ImmTAC) molecules are bi-specific biologics formed of an affinity-enhanced TCR fused to an anti-CD3 effector function. ImmTAC molecules are designed to activate human T lymphocytes and target peptides within the context of a human leukocyte antigen (HLA), thus require an intact human immune system and peptidome for suitable preclinical screening. Here we draw upon the preclinical testing of four ImmTAC molecules, including IMCgp100, the first ImmTAC molecule to reach the clinic, to present our comprehensive, informative and robust approach to in vitro preclinical efficacy and safety screening. This package comprises a broad range of cellular and molecular assays using human tissues and cultured cells to test efficacy, safety and specificity, and hence predict human responses in clinical trials. We propose that this entirely in vitro package offers a potential model to be applied to screening other TCR-based biologics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0205491

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 84

Metadata

Authors
Harper, J., Adams, K. J., Bossi, G., Wright, D. E., Stacey, A. R., Bedke, N., Martinez-Hague, R., Blat, D., Humbert, L., Buchanan, H., Le Provost, G. S., Donnellan, Z., Carreira, R. J., Paston, S. J., Weigand, L. U., Canestraro, M., Sanderson, J. P., Botta Gordon-Smith, S., Lowe, K. L., Rygiel, K. A., Powlesland, A. S., Vuidepot, A., Hassan, N. J., Cameron, B. J., Jakobsen, B. K., & Dukes, J.
Venue
PLOS ONE
Published
2018-10-15
Volume
13
Issue
10
Pages
e0205491
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2897474789
Cited by
84
References
6
FWCI
2.97
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.